Annals of Oncology· @Annals_Oncology · X·· 16 小时前评分45
正文 · 机器翻译
📢 #ESMO26 同期论文：一项随机 I 期研究，比较 telisotuzumab adizutecan（ABBV-400，Temab-A）联合 bevacizumab 与 trifluridine-tipiracil 联合 bevacizumab 在转移性结直肠癌患者中的情况。
🔗https://shorturl.at/EHTHP
@Cecchini_OncMD
115 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
2658RO按 Rapid oral 1: NSCLC, metastatic 对上
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.org791RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上
Long-term follow-up of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Updated results of a phase 1 study
https://esmocongress.esmo.org来源：Annals of Oncology · x.com